SUSAN BLANEY to Neoplasm Invasiveness
This is a "connection" page, showing publications SUSAN BLANEY has written about Neoplasm Invasiveness.
Connection Strength
0.059
-
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20; 25(21):3137-43.
Score: 0.059